This Trial is Conducted in Asia. The Aim of This Trial is to Compare the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Jun 2017
At a glance
- Drugs Insulin degludec/liraglutide (Primary) ; Insulin degludec
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 10 Jun 2017 Biomarkers information updated
- 07 Jun 2017 Planned End Date changed from 22 Nov 2017 to 21 Nov 2017.
- 07 Jun 2017 Planned primary completion date changed from 4 Oct 2017 to 3 Oct 2017.